
  
    
      
        Introduction_NNP
        For_IN many_JJ years_NNS ,_, scientists_NNS believed_VBN that_IN point_NN mutations_NNS
        in_IN genes_NNS are_VBP the_DT genetic_JJ switches_NNS for_IN somatic_JJ and_CC inherited_VBN
        diseases_NNS such_JJ as_IN cystic_JJ fibrosis_NNS ,_, phenylketonuria_NN and_CC
        cancer_NN ._. For_IN this_DT to_TO be_VB the_DT case_NN ,_, disease-associated_JJ amino_JJ
        acid_NN substitutions_NNS should_MD occur_VB in_IN functionally_RB important_JJ
        regions_NNS of_IN the_DT protein_NN products_NNS of_IN genes_NNS ._. While_IN it_PRP has_VBZ been_VBN
        shown_VBN in_IN specific_JJ cases_NNS that_IN disease-associated_JJ amino_JJ acid_NN
        substitutions_NNS affect_VBP protein_NN function_NN ,_, until_IN now_RB few_JJ
        studies_NNS have_VBP examined_VBN this_DT across_IN many_JJ genes_NNS ._. Here_RB we_PRP
        provide_VBP direct_JJ evidence_NN that_IN disease-associated_JJ point_NN
        mutations_NNS occur_VBP in_IN functionally_RB important_JJ regions_NNS of_IN the_DT
        genome_NN and_CC are_VBP not_RB distributed_VBN equally_RB across_IN the_DT coding_VBG
        regions_NNS of_IN genes_NNS ._. This_DT work_NN supports_VBZ recent_JJ efforts_NNS to_TO
        collect_VB disease_NN associated_VBN mutational_NN data_NNS in_IN databases_NNS and_CC
        suggests_VBZ that_IN many_JJ of_IN the_DT mutations_NNS represented_VBD in_IN those_DT
        databases_NNS are_VBP the_DT likely_JJ underlying_VBG molecular_JJ cause_NN of_IN
        disease_NN ._.
        Recently_RB there_EX have_VBP been_VBN a_DT number_NN of_IN commercial_JJ and_CC
        public_JJ projects_NNS aimed_VBN at_IN collecting_VBG and_CC understanding_VBG human_JJ
        genomic_JJ variation_NN [_NN 1_CD ]_NN ._. The_DT goal_NN of_IN these_DT projects_NNS is_VBZ to_TO
        provide_VB an_DT understanding_NN of_IN how_WRB genotype_NN is_VBZ associated_VBN with_IN
        disease_NN ,_, how_WRB it_PRP affects_VBZ our_PRP$ response_NN to_TO drugs_NNS and_CC how_WRB it_PRP
        affects_VBZ the_DT protein_NN products_NNS of_IN genes_NNS ._. Examples_NNS of_IN these_DT
        projects_NNS include_VBP the_DT SNP_NNP Consortium_NNP ,_, the_DT Human_NNP Genome_NNP
        Mutation_NNP Database_NNP [_NN 2_CD ]_NN ,_, many_JJ gene_NN specific_JJ databases_NNS (_( [_NN
        3_CD 4_CD ]_NN ,_, for_IN example_NN )_) ,_, and_CC both_DT public_NN and_CC private_JJ genome_NN
        sequencing_VBG efforts_NNS [_NN 5_CD ]_NN ._. Much_JJ of_IN the_DT data_NNS that_WDT is_VBZ being_VBG
        collected_VBN are_VBP mutations_NNS annotated_JJ with_IN their_PRP$ observed_JJ
        phenotype_NN ._. Automated_NNP annotation_NN methods_NNS based_VBN on_IN structural_JJ
        and_CC evolutionary_JJ parameters_NNS can_MD lead_VB to_TO insight_NN into_IN the_DT
        molecular_JJ basis_NN of_IN disease_NN ._.
        With_IN more_JJR than_IN 4_CD ,_, 000_CD ,_, 000_CD identified_VBN variations_NNS and_CC with_IN
        over_IN 20_CD ,_, 000_CD of_IN them_PRP annotated_JJ with_IN a_DT phenotype_NN ,_, we_PRP are_VBP
        facing_VBG the_DT problem_NN of_IN having_VBG many_JJ uncharacterized_JJ
        mutations_NNS ._. Algorithms_NNP are_VBP needed_VBN for_IN automatically_RB
        annotating_VBG these_DT gene_NN variations_NNS to_TO gain_VB insight_NN into_IN how_WRB
        they_PRP affect_VBP the_DT gene_NN 's_POS regulation_NN and_CC /_NN or_CC function_NN of_IN its_PRP$
        protein_NN products_NNS ._. Using_VBG many_JJ collection_NN technologies_NNS ,_,
        uncharacterized_JJ SNP_NNP data_NNS is_VBZ being_VBG placed_VBN in_IN public_JJ
        databases_NNS such_JJ as_IN the_DT Human_NNP Genome_NNP Mutation_NNP Database_NNP (_( over_IN
        20_CD ,_, 000_CD entries_NNS )_) [_NN 2_CD ]_NN and_CC the_DT National_NNP Cancer_NNP Institute_NNP 's_POS
        CGAP-GAI_NNP (_( Cancer_NNP Genome_NNP Anatomy_NNP Project_NNP Genetic_NNP Annotation_NNP
        Initiative_NNP )_) [_NN 6_CD ]_NN ._. The_DT CGAP-GAI_NNP group_NN has_VBZ identified_VBN
        10_CD ,_, 243_CD SNPs_NNP by_IN examining_VBG publicly_RB available_JJ EST_NNP (_( Expressed_NNP
        Sequence_NNP Tag_NNP )_) chromatograms_NNS ._.
        Software_NNP for_IN analyzing_VBG unannotated_JJ SNPs_NNP in_IN known_VBN disease_NN
        associated_VBN genes_NNS will_MD be_VB especially_RB useful_JJ when_WRB previously_RB
        unobserved_JJ mutations_NNS are_VBP discovered_VBN ._. Every_DT human_NN has_VBZ
        genotypic_JJ differences_NNS from_IN the_DT standard_JJ genome_NN
        approximately_RB every_DT thousand_CD base_NN pairs_NNS [_NN 7_CD 8_CD 9_CD ]_NN ._. Given_VBN
        knowledge_NN of_IN how_WRB a_DT genotype_NN differs_VBZ from_IN the_DT standard_NN ,_, it_PRP
        is_VBZ important_JJ to_TO be_VB able_JJ to_TO predict_VB which_WDT of_IN the_DT variations_NNS
        are_VBP likely_JJ to_TO be_VB the_DT cause_NN of_IN disease_NN or_CC other_JJ phenotypic_JJ
        differences_NNS ._. Evolutionary_NNP information_NN about_IN regulatory_JJ and_CC
        coding_VBG regions_NNS of_IN genes_NNS can_MD be_VB used_VBN to_TO highlight_VB certain_JJ
        mutations_NNS or_CC groups_NNS of_IN mutations_NNS that_WDT are_VBP attributable_JJ to_TO a_DT
        phenotype_NN [_NN 10_CD 11_CD 12_CD ]_NN ._.
        Early_RB tools_NNS using_VBG phylogenetic_JJ and_CC structural_JJ
        information_NN have_VBP shown_VBN promise_NN in_IN predicting_VBG the_DT functional_JJ
        consequences_NNS of_IN a_DT mutation_NN [_NN 13_CD ]_NN ._. These_DT reports_NNS predict_VBP
        that_IN anywhere_RB between_IN 20_CD -_: 36_CD %_NN of_IN non-synonymous_JJ SNPs_NNP alter_VB
        the_DT function_NN of_IN a_DT gene_NN 's_POS protein_NN product_NN ._. In_IN the_DT report_NN by_IN
        Chasman_NNP and_CC Adams_NNP ,_, evolutionary_JJ information_NN was_VBD predicted_VBN
        to_TO be_VB a_DT useful_JJ component_NN in_IN determining_VBG whether_IN a_DT mutation_NN
        is_VBZ deleterious_JJ [_NN 13_CD 14_CD ]_NN ._. Disease_NNP causing_VBG mutations_NNS are_VBP
        also_RB likely_JJ structurally_RB perturbing_VBG at_IN the_DT protein_NN level_NN [_NN
        15_CD ]_NN ._. Ng_NNP and_CC Henikoff_NNP have_VBP introduced_VBN SIFT_NNP ,_, a_DT method_NN for_IN
        predicting_VBG functional_JJ SNPs_NNP from_IN a_DT database_NN of_IN unannotated_JJ
        polymorphisms_NNS [_NN 16_CD 17_CD ]_NN ._.
        The_DT relationship_NN between_IN disease-associated_JJ mutation_NN
        positions_NNS and_CC evolutionary_JJ conservation_NN has_VBZ been_VBN reported_VBN
        in_IN specific_JJ cases_NNS ._. An_DT analysis_NN of_IN the_DT breast_NN and_CC ovarian_NN
        cancer_NN susceptibility_NN gene_NN ,_, BRCA_NNP 1_CD ,_, showed_VBD that_IN
        disease-associated_JJ mutations_NNS tend_VBP to_TO occur_VB in_IN highly_RB
        conserved_JJ regions_NNS [_NN 18_CD ]_NN ._. An_DT analysis_NN of_IN homologous_RB
        sequences_NNS in_IN the_DT androgen_NN receptor_NN has_VBZ shown_VBN similar_JJ
        results_NNS [_NN 10_CD ]_NN ._. Keratin_NNP 12_CD ,_, KRT_NNP 12_CD ,_, is_VBZ associated_VBN with_IN
        Meesmann_NNP Corneal_NNP Epithelial_NNP Dystrophy_NNP (_( MCD_NNP )_) ._. Reported_NNP
        mutations_NNS often_RB occur_VBP in_IN the_DT highly_RB conserved_JJ
        alpha-helix-initiation_JJ motif_NN of_IN rod_NN domain_NN 1_CD A_DT or_CC in_IN the_DT
        alpha-helix-termination_JJ motif_NN of_IN rod_NN domain_NN 2_CD B_NNP [_NN 19_CD ]_NN ._.
        Structure_NNP based_VBD analysis_NN methods_NNS have_VBP also_RB been_VBN used_VBN to_TO
        analyze_VB Osteogenesis_NNP imperfecta_NN associated_VBN COL_NNP 1_CD A_DT 1_CD mutations_NNS
        and_CC disease-associated_JJ P_NN 53_CD mutations_NNS (_( Mooney_NNP and_CC Klein_NNP ,_,
        unpublished_JJ )_) ,_, [_NN 20_CD ]_NN ._. Miller_NNP and_CC Kumar_NNP have_VBP reported_VBN that_IN
        disease-associated_JJ mutations_NNS are_VBP conserved_JJ in_IN seven_CD model_NN
        genes_NNS [_NN 21_CD ]_NN ._.
        To_TO determine_VB the_DT degree_NN to_TO which_WDT mutation_NN positions_NNS
        differ_VBP evolutionarily_RB from_IN other_JJ positions_NNS ,_, we_PRP have_VBP built_VBN
        alignments_NNS of_IN homologous_RB genes_NNS for_IN 231_CD disease-associated_JJ
        genes_NNS ._. These_DT multiple_JJ alignments_NNS have_VBP then_RB been_VBN used_VBN to_TO
        assess_VB the_DT difference_NN in_IN evolutionary_JJ conservation_NN for_IN
        positions_NNS that_WDT are_VBP both_DT disease-associated_JJ and_CC not_RB
        associated_VBN ._. The_DT results_NNS show_VBP that_IN ,_, in_IN general_JJ ,_, positions_NNS
        with_IN disease-associated_JJ mutations_NNS are_VBP conserved_JJ more_JJR than_IN
        the_DT average_JJ position_NN in_IN the_DT alignment_NN ._. This_DT suggests_VBZ the_DT
        most_RBS conserved_JJ mutations_NNS are_VBP likely_JJ to_TO be_VB the_DT causative_JJ
        agents_NNS of_IN disease_NN ,_, and_CC our_PRP$ data_NNS set_VBN identifies_VBZ these_DT
        mutations_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        Our_PRP$ method_NN compares_VBZ the_DT negative_JJ entropy_NN of_IN
        disease-associated_JJ columns_NNS within_IN an_DT alignment_NN to_TO other_JJ
        columns_NNS in_IN that_DT alignment_NN ._. The_DT goal_NN of_IN this_DT work_NN is_VBZ to_TO
        build_VB these_DT alignments_NNS ,_, map_NN the_DT mutations_NNS to_TO them_PRP ,_, and_CC show_NN
        that_IN disease-associated_JJ positions_NNS are_VBP ,_, in_IN general_JJ ,_,
        conserved_JJ ._. The_DT analysis_NN was_VBD performed_VBN on_IN the_DT built_VBN
        alignments_NNS and_CC the_DT results_NNS are_VBP shown_VBN in_IN Table_NNP 1_CD ._.
        To_TO collect_VB the_DT mutation_NN data_NN ,_, 231_CD genes_NNS were_VBD used_VBN for_IN
        the_DT analysis_NN ._. They_PRP were_VBD chosen_VBN because_IN they_PRP had_VBD a_DT reported_VBN
        cDNA_NN sequence_NN ,_, disease-associated_JJ mutations_NNS and_CC homologs_NNS in_IN
        SWISSPROT_NNP ._. These_DT genes_NNS are_VBP listed_VBN in_IN Table_NNP 1_CD ._. Each_DT
        alignment_NN consists_VBZ of_IN all_PDT the_DT homologs_NNS in_IN SWISSPROT_NNP as_IN
        determined_VBN by_IN a_DT BLAST_NN search_NN with_IN an_DT e-value_JJ threshold_NN of_IN
        10_CD e-_NN 15_CD ._. For_IN each_DT alignment_NN the_DT negative_JJ entropy_NN for_IN each_DT
        column_NN was_VBD calculated_VBN ._.
        The_DT conservation_NN ratio_NN parameter_NN is_VBZ defined_VBN as_IN the_DT
        average_JJ negative_JJ entropy_NN of_IN analyzable_JJ positions_NNS with_IN
        reported_VBD mutations_NNS divided_VBN by_IN the_DT average_JJ negative_JJ entropy_NN
        of_IN every_DT analyzable_JJ position_NN in_IN the_DT gene_NN sequence_NN ._. Analysis_NNP
        was_VBD performed_VBN on_IN 231_CD genes_NNS and_CC 6185_CD mutations_NNS and_CC of_IN those_DT
        we_PRP found_VBD that_DT 84_CD ._. 0_CD %_NN had_VBD conservation_NN ratios_NNS less_JJR than_IN one_CD ._.
        From_IN those_DT ,_, 139_CD genes_NNS had_VBD more_JJR than_IN ten_CD analyzable_JJ
        mutations_NNS and_CC ,_, of_IN those_DT ,_, 88_CD ._. 0_CD %_NN had_VBD conservation_NN ratios_NNS less_JJR
        than_IN one_CD ._.
        Use_NN of_IN evolutionary_JJ information_NN is_VBZ a_DT promising_JJ approach_NN
        to_TO automated_VBN characterization_NN of_IN mutations_NNS ._. These_DT results_NNS
        show_VBP that_IN although_IN conservation_NN alone_RB is_VBZ not_RB a_DT perfect_JJ
        predictive_JJ measure_NN ,_, there_EX is_VBZ useful_JJ information_NN contained_VBD
        in_IN sequence_NN alignments_NNS containing_VBG homologous_RB genes_NNS ._.
        Approaches_NNP using_VBG conservation_NN in_IN a_DT multiple_JJ alignment_NN
        should_MD work_VB better_JJR when_WRB associated_VBN with_IN other_JJ methods_NNS such_JJ
        as_IN structural_JJ analysis_NN ,_, population_NN analysis_NN and_CC
        experimental_JJ data_NNS ._. Knowledge_NNP of_IN how_WRB the_DT sequence_NN pool_NN
        clusters_NNS into_IN families_NNS may_MD increase_VB the_DT sensitivity_NN of_IN the_DT
        method_NN ._.
        Our_PRP$ measured_VBN parameter_NN ,_, the_DT conservation_NN ratio_NN ,_, is_VBZ a_DT
        quantity_NN that_IN measures_VBZ the_DT usefulness_NN of_IN a_DT multiple_JJ
        alignment_NN for_IN characterizing_VBG mutations_NNS in_IN a_DT gene_NN sequence_NN ._.
        Knowledge_NNP of_IN more_JJR mutations_NNS in_IN a_DT gene_NN does_VBZ not_RB necessarily_RB
        lower_VB the_DT conservation_NN ratio_NN ._. We_PRP expect_VBP that_DT knowledge_NN of_IN
        more_JJR mutations_NNS in_IN a_DT gene_NN will_MD increase_VB the_DT statistical_JJ
        significance_NN of_IN the_DT conservation_NN ratio_NN ._. This_DT is_VBZ the_DT likely_JJ
        underlying_VBG cause_NN of_IN the_DT result_NN showing_VBG that_IN genes_NNS with_IN 10_CD
        or_CC mutations_NNS increases_NNS are_VBP more_RBR likely_JJ to_TO have_VB a_DT
        conservation_NN ratio_NN less_JJR than_IN one_CD ._.
        The_DT alignments_NNS and_CC BLAST_NN searches_NNS are_VBP integrated_VBN on_IN the_DT
        website_NN ,_, http_NN :_: /_NN /_NN cancer_NN ._. stanford_NN ._. edu_NN /_NN mut-paper_JJ /_NN ._.
      
      
        Conclusions_NNP
        In_IN conclusion_NN ,_, there_EX are_VBP estimated_VBN to_TO be_VB 30_CD ,_, 000_CD
        non-synonymous_JJ differences_NNS between_IN an_DT individual_JJ and_CC the_DT
        draft_NN genome_NN [_NN 23_CD 5_CD 7_CD 8_CD 9_CD ]_NN ._. Determination_NNP of_IN which_WDT
        positions_NNS are_VBP likely_JJ to_TO be_VB disease_NN associated_VBN is_VBZ a_DT
        challenging_VBG and_CC important_JJ problem_NN ._. The_DT finding_VBG that_IN
        disease-associated_JJ mutations_NNS occur_VBP in_IN positions_NNS of_IN
        functional_JJ importance_NN supports_VBZ recent_JJ efforts_NNS for_IN the_DT
        building_NN of_IN methods_NNS to_TO predict_VB which_WDT positions_NNS are_VBP likely_JJ
        to_TO be_VB disease_NN associated_VBN [_NN 14_CD 13_CD 16_CD 17_CD ]_NN ._. These_DT methods_NNS
        are_VBP likely_JJ to_TO incorporate_VB protein_NN structure_NN ,_, the_DT amino_JJ acid_NN
        identity_NN of_IN the_DT mutation_NN and_CC phylogenetic_JJ information_NN ._. In_IN
        an_DT interesting_JJ twist_NN ,_, this_DT observation_NN also_RB suggests_VBZ that_IN
        this_DT data_NNS may_MD be_VB useable_JJ as_IN a_DT functional_JJ genomics_NNS tool_NN for_IN
        understanding_VBG the_DT function_NN of_IN the_DT protein_NN products_NNS of_IN genes_NNS
        on_IN a_DT molecular_JJ level_NN ._. Such_JJ a_DT method_NN would_MD use_VB the_DT inherent_JJ
        functional_JJ information_NN contained_VBD in_IN a_DT phenotypically_RB
        annotated_JJ polymorphism_NN to_TO infer_NN functional_JJ importance_NN
        within_IN a_DT gene_NN ._.
      
      
        Methods_NNP
        Non-synonymous_NNP mutations_NNS were_VBD acquired_VBN from_IN the_DT Human_NNP
        Genome_NNP Mutation_NNP Database_NNP
        http_NN :_: /_NN /_NN archive_NN ._. uwcm_NN ._. ac_NN ._. uk_NN /_NN uwcm_NN /_NN mg_NN /_NN hgmd_NN 0_CD ._. html_NN ._. 231_CD genes_NNS
        were_VBD chosen_VBN with_IN known_VBN disease-association_JJ each_DT having_VBG
        SWISSPROT_NNP homologs_NNS ,_, a_DT cDNA_NN sequence_NN and_CC mutations_NNS in_IN the_DT
        coding_VBG region_NN ._. For_IN each_DT of_IN those_DT genes_NNS ,_, all_DT known_VBN
        non-synonymous_JJ mutations_NNS were_VBD then_RB downloaded_JJ with_IN the_DT cDNA_NN
        sequence_NN for_IN that_DT gene_NN ._.
        Each_DT cDNA_NN sequence_NN was_VBD then_RB translated_VBN and_CC placed_VBN in_IN a_DT
        FASTA_NNP formatted_JJ file_NN ._. For_IN each_DT of_IN the_DT resultant_JJ files_VBZ a_DT
        BLAST_NN [_NN 24_CD ]_NN search_NN was_VBD performed_VBN against_IN the_DT SwissProt_NNP
        database_NN ._. All_DT sequences_NNS from_IN the_DT returned_VBN hits_NNS were_VBD then_RB
        stored_VBN in_IN FASTA_NNP format_NN files_NNS ._. For_IN each_DT of_IN the_DT genes_NNS that_WDT
        returned_VBD BLAST_NN results_NNS with_IN e-value_JJ scores_NNS smaller_JJR than_IN
        1_CD e-_NN 15_CD ,_, ClustalW_NNP [_NN 25_CD ]_NN was_VBD used_VBN to_TO build_VB a_DT sequence_NN
        alignment_NN ._.
        For_IN each_DT amino_JJ acid_NN in_IN the_DT position_NN of_IN interest_NN ,_, the_DT
        negative_JJ entropy_NN was_VBD determined_VBN using_VBG the_DT following_NN formula_NN
        [_NN 26_CD ]_NN :_:
        
        Where_WRB the_DT P_NN 
        i_NNP are_VBP the_DT probabilities_NNS of_IN finding_VBG a_DT
        particular_JJ amino_JJ acid_NN at_IN that_DT position_NN ._. For_IN this_DT analysis_NN ,_,
        gapped_JJ positions_NNS ,_, "_'' -_: "_'' ,_, were_VBD considered_VBN independent_JJ amino_JJ
        acids_NNS ._.
        For_IN each_DT known_VBN mutation_NN ,_, the_DT negative_JJ entropy_NN of_IN the_DT
        column_NN it_PRP occupies_VBZ was_VBD tabulated_JJ ._. The_DT average_JJ negative_JJ
        entropy_NN for_IN each_DT mutation_NN within_IN a_DT gene_NN was_VBD compared_VBN to_TO the_DT
        average_JJ entropy_NN of_IN all_DT columns_NNS satisfying_VBG the_DT criteria_NNS for_IN
        analysis_NN ._. Mutations_NNP outside_IN of_IN the_DT coding_VBG region_NN or_CC
        mutations_NNS encoding_VBG termination_NN codons_NNS were_VBD discarded_VBN ._.
        The_DT list_NN of_IN genes_NNS was_VBD then_RB sorted_VBN by_IN average_JJ negative_JJ
        entropy_NN of_IN the_DT mutations_NNS ._. We_PRP then_RB calculated_VBD the_DT
        conservation_NN entropy_NN ,_, CE_NNP ,_, using_VBG :_:
        CE_NNP =_SYM average_JJ NE_NNP of_IN mutation_NN positions_NNS /_NN average_JJ NE_NNP of_IN all_DT
        positions_NNS in_IN the_DT gene_NN sequence_NN
      
    
  
